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SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD
DISCRIMINATION IN RATS
Keli A. Herr, Ph.D.
Western Michigan University

After decades of opposition, a resurgence of interest in the psychotherapeutic potential of
LSD is gaining acceptance in the medical community. Future acceptance of LSD as a
psychotherapeutic adjuvant may be predicated on knowledge about its neural mechanisms of
action. Preclinical drug discrimination assay offers an invaluable model to determine the neural
mechanisms underlying LSD’s interoceptive stimulus effects. Unfortunately, current preclinical
literature on LSD discrimination is based on results obtained exclusively in male subjects. The
present study represents the first known preclinical assessment of possible sex differences in the
discriminative stimulus effects of LSD.
Adult female (n=8) and male (n=8) Sprague-Dawley rats were trained to discriminate
0.08 mg/kg LSD from saline under a fixed ratio 20 schedule of food reinforcement. Once
discrimination was established, substitution tests were conducted with other hallucinogens
(mescaline, DOM, psilocybin), mixed psychedelic-stimulants (MDMA, (+)-MDMA, (-)-MDMA,
(+)-MDA, (-)-MDA), synthetic cathinones (MDPV, mephedrone) and psychostimulants
(cocaine, amphetamine). Antagonist tests were conducted with serotoninergic antagonists (WAY
100,635, MDL 100,907, pirenperone) and dopaminergic antagonists (haloperidol, SCH 23390).

Stimulus substitution results indicate higher levels of LSD-substitution with other
serotonergic hallucinogens in females compared to males and some evidence for sex differences
in the level of partial substitution by synthetic cathinones and the enantiomers of MDMA and
MDA. Specifically, greater partial substitution was observed with (±)-MDMA, (+)MDMA, and
(+)-MDA, in males and greater partial substitution was observed with (-)-MDMA , (-)-MDA,
MDPV, and 4-MMC in females. Dopamine antagonists failed to block LSD in either males or
females, but had stronger rate suppressant effects in males. The 5-HT2A antagonist, MDL
100,907 blocked LSD discrimination in both males and females, although complete blockade
was evident at lower doses in males. These results suggest the relative contribution of
serotonergic versus dopaminergic activity to the LSD cue varies between males and females.
These findings may be informative for future investigations with human populations regarding
possible sex differences in the subjective effects of LSD.
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CHAPTER I
INTRODUCTION

Lysergic acid diethylamide (LSD) is one of the most potent and safest psychoactive
chemicals known to mankind. After decades of opposition, a resurgence of interest in the
psychotherapeutic potential of LSD is now evident in the clinical psychopharmacology literature.
Clinical trials are currently in progress with LSD as an adjuvant to psychotherapy in the
treatment of anxiety, depression, and drug addiction (Carhart-Harris, et al., 2016a). Increased
acceptance of LSD as a tool in psychotherapeutic settings could facilitate further discovery of the
underlying neural mechanisms involved in its unique psychoactive properties.
Undoubtedly, preclinical research utilizing animal models has proven invaluable in
discerning the neurochemical actions of psychoactive drugs. In particular, the drug
discrimination paradigm has contributed considerable knowledge about the neurochemical
substrates underlying the interoceptive stimulus effects of many drugs, including those of LSD.
Nevertheless, the precise cellular mechanisms responsible for LSD-induced hallucinations are
still not entirely understood after nearly 50 years of preclinical psychopharmacology research.
Furthermore, there are currently no known published studies regarding possible sex differences
in the discriminative stimulus effects of LSD. In fact, despite multiple calls to action to evaluate
sex as an important biological variable, most preclinical behavioral pharmacology studies
continue to use only male subjects. The National Institute of Health (NIH) and other major
research institutes have made recent steps in addressing the sex bias in preclinical and clinical
research. The primary aim of the current study was to ascertain if the psychopharmacological
profile of LSD varies between male and female Sprague-Dawley rats. The following introduction
1

will first address the relevance of sex as a biological variable in psychopharmacology
research in support of the rationale for the current study. The remainder of the
introduction will provide a historical background and broad overview of current
knowledge regarding the psychopharmacology of LSD.
Sex as a Biological Variable
Preclinical research is invaluable for the advancement of the scientific field,
especially in translating to the clinical population. Much of our understanding of the
mechanisms of drug action, behavioral responses to drugs, and potential treatments for
drug abuse begins with preclinical research. Sex differences in responsiveness to drugs
in rodents have been reported for over 50 years (Hughes, 2007). Despite this evidence,
the vast majority of behavioral pharmacology research continues to use only male
subjects and findings are generalized to female populations. Furthermore, the use of only
male subjects is not limited to pharmacological and addiction research, (Becker,
McClellan, & Reed, 2017). Progress toward the inclusion of females has remained
stagnant in all areas of preclinical research for several decades.
There are several reasons why females are omitted as subject in preclinical
research (Hughes, 2007). The most frequently cited reason is that the female estrous
cycle may confound results by causing variability in experimental data. Another reason
is the added cost of using both sexes. Lastly, earlier research failed to yield consistent
significant differences between males and females, indicting there was no reason to study
both sexes. Thus, preclinical researchers tend to conduct research investigations using
only males as subjects to avoid the aforementioned complications (Hughes, 2007).
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Previous research from both animal and human studies has indicated that males and
females differ in gonadal hormones, brain structures, neurochemistry, pharmacokinetics,
pharmacodynamics, and behavioral responses to drugs of abuse (Becker & Hu, 2008; & Hughes,
2007). Hormonal differences between males and females are perhaps a primary reason for sex
differences in response to recreational drugs. Several studies indicate that the female rat’s
estrous cycle and specifically, ovarian hormones play an important role in sex differences
observed in animal models of drug abuse (Becker & Hu, 2008; Hughes, 2007). For example, the
estrous cycle has been studied quite extensively in drug-self administration studies using
psychostimulants. Results from these studies have suggested that estrogen enhances female rat’s
drug-taking behaviors (Becker & Hu, 2008).
Recently, the National Institute of Health (NIH) created a policy mandating the
consideration of using female animals as subjects in preclinical research (NIH, 2015).
Furthermore, NIH has recognized the importance of the inclusion of females as subjects and
soon, failing to take sex into account will make applicants noncompliant when receiving NIH
funding. For all applications submitted to the NIH after January 25, 2016, the NIH expects that
sex as a biological variable will be “factored into research designs, analyses, and reporting in
vertebrate animal and human studies…Strong justification from the scientific literature,
preliminary data, or other relevant considerations must be provided for applications proposing to
study only one sex” (NOT-OD_15-102, 2015, p.1). As such, the NIH has set forth expectations
for future research to consider sex differences when planning experimental designs and data
analysis and when reporting results.
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LSD Historical Background
Lysergic acid diethylamide (LSD) was first synthesized in 1938 by Dr. Albert
Hofmann, a medicinal chemist working for the Sandoz Company in Switzerland (Hintzen
& Passie, 2010). Sandoz was interested in alkaloids obtained from ergot, a substance
produced by the fungus Claviceps purpurea. Hofmann began to combine lysergic acid,
the core chemical structure in all ergot alkaloids, with other compounds to create new
circulatory and respiratory stimulants. The twenty-fifth compound synthesized in the
course of his research was named LSD-25. However, LSD-25 failed to show any
significant results and research was discontinued. Five years later, Hofmann elected to
re-evaluate LSD-25, considering it might have useful pharmacological properties not
observed during initial investigations. While synthesizing a new batch of LSD-25, he
accidently ingested some and experienced bizarre visions for the next few hours. To
determine whether the effects he experienced were due to LSD-25, he conducted a selfexperiment with 250 micrograms (0.25 milligrams) of LSD three days later (Hintzen &
Passie, 2010). Hofmann was excited about his discovery and informed his colleagues at
Sandoz that LSD-25 may have some useful implications (Hofmann, 2009).
In 1947, Sandoz marketed LSD under the tradename Delysid (D-Lysergsaurediathylamid) and distributed it in large quantities to scientists in the medical community.
It was promoted as an experimental tool that could enhance understanding of mental
illnesses at the chemical and behavioral level, such as schizophrenia, psychoses, and
neuroses (Hintzen & Passie, 2010). Additionally, LSD was used as a psychotherapy tool
to promote psychological insight and for the treatment of alcoholism. During 1950s,
interest from other sectors of society developed. The Central Intelligence Agency (CIA)
4

conducted experiments with LSD as a potential truth serum or mind-control drug in a secret
program coded MK-ULTRA. However, in the mid-1960s the program was discontinued because
it failed to produce expected results (Hintzen & Passie, 2010).
By the mid-1960s, LSD had moved from the laboratory into the streets and quickly
became a popular recreational drug associated with the counterculture movement (Hintzen &
Passie, 2010). LSD was further stigmatized by the public media due to adverse . In 1966, LSD
was made illegal under provisions of the Federal Drug Abuse Control Amendments and it
quickly fell out favor among medical and scientific communities. In 1970, the Drug
Enforcement Agency (DEA) under the Controlled Substances Act classified LSD as a Schedule I
drug. During the 1970s, as a consequence of the political pressure due to the increasing
recreational use, clinical research with LSD in humans virtually stopped. However, recreational
use of LSD continued (Hintzen & Passie, 2010) and remains prevalent, particularly among
young adults. According to SAMSHA 2014 National Survey on Drug Use and Health (NSDUH),
an estimated 287,000 Americans reported current LSD use (defined as use within the last 30
days).
Despite the current status as Schedule I drug, LSD does not meet any of the criteria for a
Schedule I drug (i.e., high abuse potential, no accepted medical uses or benefits, there is a lack of
accepted safety for its use under medical supervision) for several reasons. First, LSD can cause
significant dangers to the user, but not as a result of any pharmacological toxicity like other
drugs of abuse (Nichols, 2004). Secondly, LSD does not directly cause overdose deaths,
although deaths have occurred in unsupervised settings, mainly due to impaired judgment. LSD
has a low risk for acute toxicity and chronic use does not cause organ damage. Lastly, LSD is
not addictive and cessation following repeated use does not produce withdrawal symptoms.
5

Moreover, in animal models of self-administration, LSD is typically not reinforcing to
animals. However, LSD can produce tolerance after repeated use, where higher doses are
required to obtain the same effects (Nichols, 2004).
LSD Pharmacology
LSD is classified as a hallucinogenic drug that alters sensory processing in the brain, and
causes perceptual disturbances in visual and auditory modalities, distorted thinking, mood
instability, and a loss of contact with reality (Nichols, 2004). The classic hallucinogens are a
diverse collection of substances with structural similarities to serotonin or the catecholamines.
The classical hallucinogens consist of two broad categories, indolealkylamines (also called
indoleamines) and phenylalkylamines, each with subclassifications based on structural
differences (Glennon, 1994). The indolealkylamines consist of several subclasses, including
tryptamines (e.g., psilocybin, dimethyltryptamine) and ergolines (e.g., LSD). The
phenylalkylamines consist of phenylethylamines (e.g., mescaline) and phenylisopropylamines
[e.g., 1-(2,5-dimethoxy-4-methyl-phenyl)-2-aminopropane (DOM)]. Despite differences in their
chemical structure and potency, the classic hallucinogens tend to produce similar psychological
effects through similar pharmacological actions in humans and animals (Nichols, 2004).
LSD can be administered by various routes. Oral administration is most common,
through blotter paper, sugar cubes, or by pill (Hintzen & Passie, 2010). In animal research, LSD
is typically administered parenterally, either through intraperitoneal (i.p.), intravenous (i.v.), or
intramuscular (i.m.) injection. LSD is remarkably potent. In humans, a typical oral dose is
between 100-250 micrograms (g). It is absorbed rapidly from the gastrointestinal tract and
distributed throughout the body within 60 minutes. LSD diffuses easily into the brain,
however only about 0.01% of the original dose reaches the brain. Following ingestion, the
6

largest concentration of LSD is in the liver, where the drug is metabolized before it is excreted
to 2-oxo-3-hydroxy-LSD. In humans, the biological half-life is estimated to be 2-5 hours and
it is eliminated rapidly from the body, with a typical duration of action ranging from 9 to 36
hours. In rodents, LSD’s half-life is reported to be approximately 15 minutes (Hintzen & Passie,
2010).
Psychological Effects
In humans, LSD exerts a wide range of psychological effects that include tactile, visual,
and auditory alterations in the perception of external stimuli, synesthesia, changes in mood and
cognition, illusions, time distortions, and visual hallucinations (Nichols, 2004). LSD’s
psychological effects depend on two key factors: the mindset of the user (i.e., personal
expectations, and mood) and the ‘setting’ or environment where the user administers LSD.
Sometimes unpleasant psychological reactions occur, including panic, confusion, and anxiety.
Alterations of consciousness and cognition produced by hallucinogens can also mimic certain
psychological disturbances observed in psychotic disorders, such as schizophrenia. Furthermore,
hallucinogenic drugs have been reported to induce the onset of psychosis in people predisposed
to schizophrenia (Nichols, 2004).
Although the effects of LSD are unpredictable and vary among individuals, higher doses
typically produce more intense effects (Hintzen & Passie, 2010). LSD’s psychological effects
are typically characterized with four phases. In the first phase, beginning shortly after
administration of LSD, and lasting up to two hours, the user observes a release of inner tension.
Other characteristics of this phase include laughing or crying, a feeling of euphoria, restlessness,
heightened awareness of the environment, and enhanced connection with others. The second
phase begins between 30 to 90 minutes after ingestion and is usually marked by perceptual
7

distortions, such as visual illusions and changes in shapes and colors. The third phase begins
three to four hours later and the user often perceives a distorted sense of time, in which time
seems to move slowly. Additionally, this phase may produce mood swings, ego disintegration,
and a loss of contact with reality. Users often refer to this phase as reaching ‘peak’, in which the
maximum effects of LSD are perceived. Finally, four to six hours after administration the effects
of LSD begin to lessen and the user begins to return to normal (Hintzen & Passie, 2010).
Physiological Effects
LSD produces physiological changes about 30 minutes after drug administration (Hintzen
& Passie, 2010). Sympathetic effects include blurred vision, palpitations, increased blood
pressure and heart rate, and pupillary dilation. Parasympathetic effects include nausea, loss of
appetite, vomiting, headache, dizziness, sweating, and muscle tension. The intensity of
autonomic effects is dose-dependent (Hintzen & Passie, 2010).
In rats, LSD produces several distinctive behaviors, including head twitches, ‘wet dog
shakes’ involving the whole body, rotational spinning in circles, flat body posture, increased
startle response, and a reduction in locomotor and exploratory activity (Krebs-Thomson &
Geyer, 1996; & Silverman, 1988).
Toxicity and Addiction
LSD is remarkably a nonlethal substance with minimal toxicity. The lethal dose
(LD50) of LSD varies across species and is primarily related to brain weight rather than
body weight (Hintzen & Passie, 2010). LD50 in rats is 15.5 mg/kg and in humans, the
LD50 has been suggested to be around 14,000 micrograms, which is equivalent to about
140 typical LSD doses. There are no reported human deaths directly due to LSD
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overdose. Most LSD-related fatalities reported are a result of adverse interactions with other
drugs, accidental death, or suicide (Hintzen & Passie, 2010).
There are no withdrawal symptoms associated with LSD use, although tolerance to its
hallucinogenic effects develops rapidly after 4 to 7 days of repeated drug use (Hintzen & Passie,
2010). Tolerance to LSD usually lasts for only about three days, after which its effects can be
experienced again with a typical dose level. Cross-tolerance occurs between LSD and other
classic hallucinogens, such as psilocybin (Hintzen & Passie, 2010).
LSD’s Neurochemical Actions
The neurochemical actions of LSD are unique, complex, and not fully understood in
humans or non-humans. In 1954, Wooley and Shaw recognized that LSD and serotonin (5-HT)
were structurally similar. They hypothesized that LSD somehow blocked the actions of
serotonin. This discovery of the structural relationship between LSD and 5-HT catalyzed a
neuroscience revolution because neurochemistry was first linked to behavior and mental illness,
such as schizophrenia instead of environmental factors (Nichols, 2004). Additionally, the
hypothesis emerged that hallucinogens may act through a common serotonergic mechanism.
However, the restrictions placed upon LSD in the 1960s have made it virtuously impossible to
investigate its neurochemical actions in humans. Thus, the majority of studies investigating the
LSD’s neurochemical actions have been conducted using non-humans
Currently, the general hypothesis among researchers is that LSD’s hallucinogenic effects
are likely due to its actions as an agonist on 5-HT2A postsynaptic receptors in the brain
(Halberstadt, 2015; Hintzen & Passie, 2010; & Nichols, 2004). Additionally, LSD has a
complex pharmacological profile that influences the majority of 5-HT receptors, including, 59

HT2c 5-HT1A, 5- HT1B, 5-HT1D, 5-HT5A, 5-HT6, and 5-HT7. LSD also has affinity for
dopamine D1, D2, D3, D4, and alpha2 receptors (Hintzen & Passie, 2010; Nichols, 2004).
Therefore, the complexity of LSD’s mechanism of action has been a significant topic of
research. Researchers have sought to explain how a drug can be so potent and have
profound effects on consciousness and perception, but have a high affinity for multiple
receptors in the brain.
LSD possesses a complex pharmacological profile that includes direct activation
of 5-HT2A receptors and indirect activation of other receptors and their subtypes through
second-messenger systems. The 5-HT2A receptors presumably play an important role in
consciousness and perception, as they are localized on cortical pyramidal cells as well as
in the thalamus, particularly in the reticular nucleus (Nichols, 2004). The reticular
nucleus acts as a filter that controls the intensity and number of signals entering the
thalamus through a negative feedback mechanism. The thalamus processes sensory
inputs, including visual, auditory, and somatosensory, and receives afferents from the
raphe nuclei (RN) and the locus coeruleus (LC). Although the majority of studies
suggest that the prefrontal cortex and thalamus are primarily responsible for the actions
of LSD, there is also evidence that the LC contributes to LSD’s effects. The LC sends
norepinephrine (NE) projections to all parts of the brain (Nichols, 2004).
Studies have shown that serotonin both hyperpolarizes and depolarizes layer V
pyramidal neurons by acting on the 5-HT1A and 5-HT2A channels respectively (Nichols,
2004). LSD acts as an agonist on 5-HT1A receptors in the LC, the RN, and frontal cortex
by inhibiting firing and 5-HT release. Normal firing of raphe cells in an awake animal
causes 5-HT to be released into cortical areas. The administration of classic
10

hallucinogens suppresses raphe cell firing either directly through activation of serotonin
receptors or indirectly by stimulation of inhibitory GABA neurons (Nichols, 2004).
LSD stimulates 5-HT2A receptors on glutamate axon projections from the thalamus. This
causes the cortical pyramidal cells to become excited, while at the same time releases glutamate
into cortical neuronal fields (Nichols, 2004). Normally, thalamic projections fire in response to
sensory information processed by the thalamus. LSD can cause glutamate to be released in the
absence of an appropriate stimulus. As a result, LSD enhances sensitivity/excitability of the
cortical processing while at the same time causes glutamate to be released from thalamic
afferents that normally signal incoming sensory information to be processed (Nichols, 2004). As
a result, LSD leads to an overload of sensory processing capacity in the thalamus, causing
dramatic changes in consciousness and perception.
Brain Imaging Studies
In a recent study, researchers from Imperial College London conducted a series of
experiments using three neuroimaging techniques: arterial spin labeling (ASL), blood oxygen
level-dependent (BOLD) measures, and magnetoencephalography (MEG), neuroimaging
methods were used to investigate the acute effects of LSD in the brains of 20 healthy volunteers
(Carhart-Harris, et al., 2016b). Neuroimaging scans were obtained on two separate days;
placebo was administered on the first day and 75 g LSD (i.v.) was administered the next day.
Results suggested that under normal conditions, visual information is processed in the visual
cortex. However, under the influence of LSD, there was an increased blood flow toward the
visual cortex, and many additional brain areas contributed to visual processing. Additionally,
normally the brain consists of independent networks that perform separate perceptual functions.
However, under the influence of LSD these independent networks became more unified in
11

processing sensory information. The participants in the study felt a sense of
connectedness with their own environment. This was proportional to a decrease in neural
firing produced by LSD (Carhart-Harris, et al., 2016b). Thus, marked changes were
observed in neuron electrical activity and network communication patterns were altered
because of LSD. This study has helped confirm what has been discovered in preclinical
studies.
In behavioral pharmacology, several assays are used to catalogue the effects and
to study the underlying mechanisms of drug action with LSD and other psychoactive
drugs. These assays include locomotor activity, prepulse inhibition, and drug
discrimination. The majority of what we know today about LSD mechanism of action is
derived from studies that have employed the drug discrimination assay.
Drug Discrimination
Drug discrimination (DD) is a popular and reliable assay that has been used since
the 1960s to investigate the subjective or interoceptive effects of psychoactive drugs
(Glennon & Young, 2011). A psychoactive drug that alters the central nervous system
(CNS) may produce a variety of changes in the user’s mood, perception, and/or behavior.
When drug effects are paired with a specific behavior, such as pressing a lever, and that
behavior is reinforced, the likelihood of making that same response under the influence of
those effects is increased. In other words, the effects produced by a drug can function as
a discriminative stimulus that alters the behavior of the subject and can set the occasion
for which a specific response will be reinforced. Therefore, DD procedures are designed
to approximate the subjective effects of psychoactive drugs, in both humans and nonhumans, by establishing a drug as a discriminative stimulus. (Glennon & Young, 2011).
12

The most commonly used procedure is the two-lever drug discrimination paradigm. In
this procedure, animals are trained daily during 20 min sessions, in which lever pressing is
reinforced by the presentation of food pellets (Glennon &Young, 2011). Discrimination training
reinforces responding on one lever following drug administration, and responses on the other
lever after vehicle (i.e. saline). Therefore, the training drug serves as a discriminative stimulus
or a cue that influences a specific behavioral response. Over time and after many training
sessions, a discrimination develops between the administration of the training drug and vehicle
(saline) (Glennon & Young, 2011).
After animals are trained to discriminate a specific dose of a training drug from its
vehicle, several experiments or tests can be performed. Test sessions are interspersed between
training sessions and typically occur two times per week. The first procedure is used to test for
stimulus substitution (or stimulus generalization tests). Tests of stimulus substitution are
performed to determine whether a novel drug is like the pharmacological effects of the training
drug. Typically, when the animal is presented a novel substance, responding 80% or higher on
the drug-appropriate lever indicates that the compound ‘substitutes’ and is pharmacologically
like the training drug (Glennon & Young, 2011). In other words, the animal generalizes the
stimulus effects of the novel compound to those of the training drug. By testing animals at
several doses of a novel compound, and recording response selection, a dose-response curve and
the degree of drug substitution can be generated.
After animals are reliably trained, two important considerations in substitution tests can
be investigated. First, a thorough dose-response investigation of the training drug can be
generated (Glennon & Young, 2011). This is calculated by administering lower and higher doses
of the training drug. For example, when lower doses of the training drug are administered,
13

animals typically make fewer responses on the ‘drug-appropriate lever’ and at a very low dose of
the training drug animals will respond on the ‘vehicle-appropriate lever’. Dose-response curves
can be used to estimate the median effective dose (ED50) in which 50% of the animals respond
on the drug-appropriate lever. A second important consideration is investigating the duration of
action of the training drug. This is called a time-course curve which can be determined by either
using shorter or longer pre-session injection times with the training drug or test compounds.
Time course of any drug stimulus cue can be characterized by its latency of onset of action, peak
activity, and total duration of pharmacological effects (Glennon & Young, 2011).
Tests of stimulus antagonism can be used to infer the receptor actions of the training
drug. Drugs that are known to block the receptor actions of known neurotransmitters are
administered prior to administration of the training drug (Glennon & Young, 2011). An
antagonist is said to block the stimulus effects of the training drug if the animal responds 80% or
higher on the vehicle-appropriate lever. DD studies have been applied successfully to the study
of LSD, and have been a reliably tool for discovering the mechanisms of action.
There are several advantages to implementing the DD assay. First, the ease of use;
in general, DD studies are relatively easy to conduct and require little specialized skills,
also these procedures are usually noninvasive by avoiding surgical methods (Glennon &
Young, 2011). A second advantage is specificity of action; highly sensitive and exhibits a
unique molecular specificity. Drugs that have common sites of action produce similar
discriminative effects, also the potency of a drug in producing discriminative effects is
proportional to its affinity for the receptor and intrinsic activity. Another advantage is
measurement of in vivo mechanisms of effect; allows investigation of the total effect of
the drug without limiting the study to one or a few targeted structures, or to one or a few
14

neurotransmitters. DD provides useful information about the total in vivo mechanisms
underlying the psychotropic effects of a drug, for example, mechanisms at different levels
determine the behavioral effects of drugs, from molecular (site of action) to the cellphysiological (brain circuitry) to the total state effect (anxiety, hallucination, etc.), A fourth
advantage is there is independence b/w choice and rates of responding; the discriminative effects
of a drug are usually independent from rates of responding such that drugs that depress
responding do not normally interfere with DD.
A third advantage is it has a high predictive validity; results obtained from DD animal
studies are generally qualitatively and quantitatively consistent with those obtained using
analogous procedures in humans, also DD procedures in animals have a high predictive validity
regarding the effects of treatments on drug self-administration in animals. Lastly the DD has the
ability to qualitatively compare the effects of different drugs, mixtures of drugs, or different
doses of the same drug; animals can be trained to discriminate a drug from vehicle, but also to
discriminate the effects of 1 dose of a drug from another dose of the same drug, the effects of one
drug from the effects of another drug (‘OR-discrimination’), the effects of a mixture of drugs
from vehicle (‘AND-discrimination’), or the effects of a mixture of 2 drugs from the effects of
each drug separately (‘AND-OR-discrimination’). These types of discrimination allow
investigation of a wide variety of scientific questions regarding not only the mechanisms of
discriminative effects of specific drugs, but also the nature of the discrimination itself (Glennon
& Young, 2011).
The DD assay is not without limitations. A major limitation is the extensive amount of
time required to conduct and complete a single study. For example, in most cases it takes
approximately three months to train animals to reach training criteria before testing can begin.
15

Additionally, the time requirement is further prolonged once discriminative training is
established because test sessions are only conducted twice per week.
LSD and Drug Discrimination
It has long been established that LSD can function as a discriminative stimulus in the rat
(Hirshorn & Winter, 1971). The development of the DD assay in animals and the discovery of
specific serotonin ligands have facilitated the identification of the 5-HT receptor subtypes that
principally mediate the interoceptive effects of LSD. LSD has been studied quite extensively in
DD research because its interoceptive cue is reliable, robust, and reasonably selective (Holohean,
White, & Appel, 1982). DD research on LSD has facilitated efforts to understanding the
mechanisms of action that mediate many of its complex interoceptive effects of it (Nichols,
2004). Over the past 50 years, research studies have demonstrated central role for 5-HT
receptors in the interoceptive stimulus effects of LSD (Nichols, 2004). As mentioned above,
LSD exerts is hallucinogenic drug cues primarily on the 5-HT2A receptor. However, LSD has
been referred to as a complex compound stimulus because unlike the other classic hallucinogens
LSD exerts its effects on many other neurotransmitters (Halberstadt & Geyer, 2011).
One of the first studies to demonstrate that LSD could function as a discriminative
stimulus was conducted by Hirschhorn and Winter (1971). In this study, rats were
trained to discriminate LSD or mescaline from saline using a two-lever DD assay. The
results indicated that LSD and mescaline produced similar interoceptive cues in the rat.
The authors concluded that LSD and mescaline might have a common mechanism of
action due to cross-generalization and cross-tolerance (1971). Subsequent studies
demonstrated that serotonergic antagonists, such as methiothepin, methysergide,
cyproheptadine, and cinanserin blocked the stimulus effects of LSD (Kuhn, Winter, &
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Appel, 1978). These findings indicate that the discriminative stimulus effects of LSD were due
to its effects on 5-HT.
Subsequent research by, Glennon, Titeler, and McKenney (1984) investigated
substitution tests with 22 hallucinogens in rats trained to discriminate DOM from saline. They
concluded that the 5-HT2 receptor was important for mediating the effects of LSD and other
hallucinogens due to strong correlation between the affinity of LSD and other hallucinogens for
the 5-HT2 receptor and their potency in humans (1984). This study was important because it led
to the discovery of 5-HT2 receptor subtypes, such as 5-HT2A and 5-HT2C. The demonstration that
hallucinogens can act as agonists at both subtypes raised the question regarding the relative
contributions of these 5-HT2 receptor subtypes to the discriminative stimulus of LSD (Nichols,
2004).
A series of studies were conducted by Fiorella, Rabin, Winter (1995b) to investigate the
correlation between the effectiveness of ten 5-HT2 antagonists in blocking stimulus control by
LSD with their selectivity for the 5-HT2A and 5-HT2C receptor subtypes. The results suggested
that the 5-HT2A receptor could only account for 56% of the variance of the LSD-antagonists, and
5-HT2C receptor did not account for the remaining variance mediated by the LSD interoceptive
cues. Thus, these results suggested that 5-HT2A receptor is primarily responsible for mediating
the discriminative stimulus effects of LSD. However, interactions with other receptor sites may
amplify the stimulus effects of LSD (Marona-Lewicka, and Nichols, 1995; Marona-Lewicka,
Thisted, & Nichols, 2005; Marona-Lewicka, & Nichols, 2007; Marona-Lewicka, Chemel &
Nichols, 2009; and Winter and Rabin, 1988). Moreover, there is considerable evidence that the
5-HT1A receptor subtype as well as dopamine receptors contribute to the discriminative stimulus
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effects of LSD (Nichols, 2004; Marona-Lewicka, Thisted, & Nichols, 2005; MaronaLewicka & Nichols, 2007 & Reissig, Eckler, Rabin, & Winter, 2005).
LSD is unique compared to other hallucinogens because it has affinities for other
monoamine receptors other than the 5-HT2A that may be responsible for mediating the
interoceptive cues (Nichols, 2004). As mentioned above, LSD has substantial affinity for
a variety of other receptors, including all 5-HT receptor subtypes, except 5-HT3 and D1,
D2, D3, and D4 receptors (Nichols, 2004). Thus, LSD’s relatively indiscriminate
receptor-binding profile suggests that it exerts its effects as a compound stimulus
contributing to its overall effect (Halberstadt and Geyer, 2011).
Reissig, Eckler, Rabin, and Winter (2005) conducted a study investigating the
involvement of the 5-HT1A receptor using the DD procedure. Combination and
substitution tests were conducted using the 5-HT1A agonists, 8-OH-DPAT, buspirone,
gepirone, ipsapirone and the 5-HT1A antagonist WAY-100,635 to characterize their
effects on LSD discrimination
The results indicated that stimulus control by LSD was augmented by all 5-HT1A receptor
agonists, while the 5-HT1A antagonist WAY-100,635 abolished this effect. Thus, the 5-HT1A
receptor appears to contribute to the discriminative stimulus effects of LSD. However, their
precise role is still not well understood (Nichols, 2004).
Previous research has also suggested that LSD has a time-dependent dopaminergic
component. LSD’s effects in humans have been reported to consist of two temporal phases: an
early “psychedelic phase” followed by a late “paranoid” phase (Marona-Lewicka, Thisted, &
Nichols, 2005). In contrast, the effects of other typtamine and phenethylamine hallucinogens
have been reported to consist of a single temporal phase. To further explore this phenomenon,
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Marona-Lewicka et al. (2005) investigated the two temporal phases in a DD study using rats.
Rats were divided into two groups and the first group was trained to discriminate 0.08 mg/kg
with a 30-min pretreatment time and a second group was trained to discriminate 0.16 mg/kg with
a pretreatment time of 90-min. The results suggested that lengthening of the pretreatment time
of LSD to 90-min resulted in the emergence of a dopaminergic interoceptive cue, as evidenced
by the substitution of dopamine receptor agonists. For example, the D2 agonists apomorphine,
N-propyldihydrexidine, and quinelorane all fully substituted only in the rats trained to
discriminate LSD with a pretreatment time of 90-min. Additionally, in rats trained with a
pretreatment time of 30-min, the LSD stimulus cue was blocked by 5-HT2A antagonists. In
contrast, in rats trained with a 90-min pretreatment, the LSD stimulus was not fully blocked by
5-HT2A antagonists. These findings suggest LSD’s discriminative stimulus effects can be
characterized by two temporal phases, the first one being mediated predominantly by 5-HT2A
receptors and the later phase mediated primarily by D2 receptors.
Marona-Lewicka and Nichols, (2007) further investigated the delayed temporal
dopaminergic effects. Similar to the Marona-Lewicka et al. (2005), two groups of rats were
administered LSD at 30-min and 90-min pretreatment time. In this study, many agonists and
antagonists were investigated. The results suggested that classical hallucinogens, such as
psilocybin and mescaline fully substituted in rats trained with a pretreatment time of 30-min, but
not in rats trained with a pretreatment time of 90-min. Additionally, dopamine receptor agonists,
such as MDMA, cocaine, ABT-724, aripiprazole, dihydrexidine, WAY, 100635, and SKF 38393
fully or partially substituted in rats trained with a 90-min pretreatment time, but not in the rats
trained with a 30-min pretreatment time (2007). Thus, these data suggested the complex
pharmacological profile of LSD allows for 5-HT and DA receptor activation mediate the
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different temporal phases of LSD discrimination in rats. However, little is known whether LSD
affects dopamine receptors directly or indirectly through modulatory effects of 5-HT2A receptors.
The majority of DD studies investigating the subjective effects of LSD has exclusively
used only males as subjects. Thus, there is currently a significant gap in preclinical research
concerning sex as a biologically relevant variable in the discriminative stimulus effects of
hallucinogens, especially LSD.
Sex Differences in Drug Discrimination
The majority of previous research using the DD assay has been conducted using
only males as subjects. In a recent review article, Bevins and Charntikov (2015)
investigated sex differences in the drug discrimination literature. Only 17 out of
thousands of published scholarly research articles were found to include female animals.
Of the 17 articles, sex differences were found in only a few of these studies investigating
cocaine, morphine, amphetamine, and MDMA subjective effects (Broadbear, Tunstall,
and Beringer, 2011; Craft, Kalivas, & Stratmann, 1996; Craft and Stratmann, 1996; Craft,
Heideman, & Bartok, 1999; Krivsky, Stoffel, Sumner, Inman, & Craft, 2006). Thus,
potential sex differences in these DD studies have been investigated. However, consistent
effects have not been replicated, precluding generalization of these findings.
Craft and Stratmann (1996) conducted a study investigating discriminative
stimulus effects of cocaine in male and female adult Sprague-Dawley rats. The results
indicated that females acquired cocaine discrimination slightly faster than males,
however the difference was not statistically significant. Additionally, the effective dose
(ED50) was the approximately the same between the sexes. Of particular interest,
cocaine’s duration of action was significantly shorter in females than in males (Craft and
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Stratmann, 1996). These findings suggest that males and females may differ in the effects of
cocaine due to hormonal or pharmacokinetic factors.
Another study conducted by Craft, Heideman, and Bartok (1999) investigated sex
differences in gonadal hormones on the discriminative stimulus effects of morphine. Adult male
and female Sprague-Dawley rats were gonadectomized (GNDZ) or sham-gonadectomized
(SHAM), then trained to discriminate morphine. The results suggested that the ED50 was
significantly lower in intact females than in males. Additionally, sex differences were found in
the substitution tests with agonists buprenorphine and nalbuphine. These drugs substituted in
nearly all females (GNDZ and SHAM) and in all the SHAM males, but only four out of the
seven GNDZ males. Also, most of the opioid agonists used were significantly more potent in
decreasing response rates in the male groups than in the female groups. At the end of the study,
hormone replacement for the GNDZ females reinstated the estrous cycle, however it did not
change the ED50 for morphine discrimination (1999). Therefore, these results suggested that few
sex differences were due to hormonal differences. Rather, sex differences may be due to
differences in reinforcement frequency between saline and drug conditions observed only in the
males.
In a more recent study, Broadbear, Tunstall, and Beringer (2010) investigated the role of
the hormone oxytocin in the subjective effects of MDMA in male and female Sprague-Dawley
rats using a three-lever DD assay. Male and female rats were trained to discriminate MDMA
from amphetamine (AMPH) and saline. The results suggested sex differences in the doseresponse curves of both MDMA and AMPH, with females being more sensitive to the subjective
effects of these drugs. Additionally, males were more sensitive to the rate-suppressing effects of
MDMA, AMPH, carbetocin, and atosiban than females (2010). These findings suggest that
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females are more sensitive to the psychological effects of MDMA than males and males
are more sensitive to the physical effects of MDMA than females. This may be due to
pharmacokinetic factors of MDMA.
Relatively few studies have been conducted using both males and females in DD
research. The lack of data and insufficient replication of studies investigating sex
differences make data interpretation difficult. To date, no known studies investigated sex
differences in the discriminative stimulus effects of LSD. However, a few studies have
been conducted using other behavioral assays to study sex differences on LSD effects.
LSD Effects in Females
A few studies have investigated sex differences in LSD’s behavioral effects using
other behavioral assays, such as locomotor and exploratory behavior, prepulse inhibition,
and place conditioning (Meehan and Schechter, 1998; Palenicek, Hlinak, BubenikovaValesova, Novak, and Horacek, 2010). For example, Meehan and Schechter (1998)
established that sex differences exist in LSD-induced conditioned place preference (CPP)
in Fawn Hooded (FH) rats. FH rats were selected for that study because they have a
genetic deficiency in serotonergic activities. Results suggested that LSD produced place
preference only in the male FH rats. The authors suggested sex differences may be due
to serotonergic deficits in FH rats or due to the estrous cycle decreasing metabolism of
serotonin in the rat central nervous system (Meehan and Schechter, 1998).
Another study conducted by Palenicek et al. (2010) examined sex differences in
the behavioral effects of LSD on exploratory behaviors and an acoustic startle reaction in
rats. The main sex differences observed were in locomotor and exploratory behavior.
Females were less sensitive to the hypolocomotor effects of LSD and displayed a greater
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increase in exploratory behavior than males. Additionally, females had lower sensitivity to the
disruptive effects of LSD on an acoustic startle reaction compared to males (Palenicek et al.,
2010).
The need for female inclusion in preclinical research is readily apparent. Failure to
include females is a major limitation in behavioral pharmacology research. Investigating
potential sex differences in animals may translate to clinical research. Currently, little is known
about sex differences with regards to the subjective effects of drugs, especially LSD.
Uncovering evidence may aid in our understanding of the mechanisms of action, subjective, and
behavioral effects of LSD. Previous research using behavioral assays has suggested that sex
differences exist in some of the behavioral effects of LSD. The primary aim of the present study
was to explore possible sex differences in the discriminative stimulus effects of LSD, and in
relative contribution of serotonergic and dopaminergic actions to these effects. Drugs with
differential actions on 5-HT and DA receptors were evaluated in male and female SpragueDawley rats trained to discriminate LSD.
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CHAPTER II
METHODS
Subjects
Eight adult males (280-300g) and eight adult females (160-190g) Sprague-Dawley rats
(Charles River Laboratories Inc., Kingston, NY, USA) were housed individually in
polycarbonate cages lined with corn cob bedding (Harlan Teklad, Conrad, Iowa). Males and
females were housed in separate colony rooms in the animal facilities maintained at constant
temperature (20±2 ºC) and humidity (50±5 %) under a 12:12 light/dark cycle with lights on from
7:00a.m. to 7:00 p.m. Water was provided ad libitum in the home cages. Commercial rodent diet
(Purina® 5001, Richmond, Indiana) was restricted to daily feeding to maintain animals at 8090% of free-feeding weights. All procedures were reviewed and approved by the Western
Michigan University Institutional Animal Care and Use Committee and were in accordance with
the guidelines of the Guide for the Care and Use of Laboratory Animals (National Research
Council of the National Academics 2011) and EU Directive 2010/63/EU.
Apparatus
Training and testing were conducted in 16 sound-attenuated operant conditioning
chambers (ENV-001; MED Associates Inc., Georgia, VT, USA). Males and females were tested
in separate rooms and at different times. Chambers were equipped with two retractable levers
and a food pellet dispenser located on the front panel, a house light (28V), and fan. Reinforcers
for lever pressing consisted of 45-mg Dustless Precision Pellets® (Product# F0021, BioServ,
Flemington, NJ). Experimental events were programmed and controlled using Med-PC software
(version IV; MED Associates Inc., St. Albans, VT, USA).
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Drugs
Lysergic acid diethylamide (LSD), 2,5-Dimethoxy-4-methylamphetamine (DOM),
mescaline, (±)3,4-methylenedioxymethamphetamine (±)MDMA, (+)3,4methylenedioxymethamphetamine (+)MDMA, (-)3,4-Methylenedioxymethamphetamine ()MDMA, methylenedioxypyrovalerone (MDPV), mephedrone (4-MMC), (+)3,4methylenedioxyamphetamine (+)-MDA), (-)3,4-Methylenedioxyamphetamine (-)-MDA),
psilocybin, cocaine, d-amphetamine (AMPH), (see Table 1) were generously provided by the
National Institute on Drug Abuse Drug Control Supply Program (Bethesda, MD). All
substitution drugs were dissolved in bacteriostatic 0.9% sodium chloride and administered by
intraperitioneal (i.p) injection with a 15-min pre-session injection interval in a 1 ml/kg injection
volume.
Antagonist drugs (see Table 2) WAY-100,635-HCL, MDL-100,907, haloperidol, SCH23390-HCL, and pirenperone. SCH-23390-HCL, and haloperidol were provided by Sigma
Aldrich Corporation (St. Louis, Missouri), WAY-100,635-HCL were provided by Santa Cruz
Biotechnology, Inc. (Dallas, Texas), and MDL-100,907 and pirenperone were provided by
NIMH Chemical Synthesis and Drug Supply Program (Research Triangle Park, North Carolina).
SCH-23390-HCL and WAY-100,635-HCL were dissolved in 0.9% saline and haloperidol was
dissolved in 0.1% HCL, and MDL-100,907, and pirenperone were dissolved in a few drops of
acetic acid diluted in H20. All antagonist drugs were administered i.p. injection with a 60-min
pre-session injection interval (except pirenperone 30-min pre-session) in a 1 ml/kg injection. All
doses were calculated based on the weights of the salts.

Operant Training Procedures
25

All chambers and levers were wiped clean with 35% isopropyl alcohol after every
experimental session to attenuate olfactory cues remaining on the levers and in the testing
environment. To control for olfactory cues between males and females, as mentioned above
males and females were housed in different colony rooms, run at separate times, in separate
chamber rooms, and in separate chambers. It is important to control for olfactory cues between
the sexes because pheromone scents can confound experimental data by interrupting physiologic
and behavioral responses (Bind, Minney, Rosenfeld, & Hallock, 2013).
Preliminary training. Subjects were acclimated to the operant chambers for two 60-min
sessions, one per day for two consecutive days. During these two sessions, no levers were
extended and food pellets were delivered under a fixed-time 60 s (FT60) schedule to familiarize
the animals with the location and sound of the food hopper. The criterion for proceeding to lever
press training consisted of each rat consuming all pellets from the magazine by the end of the 60min session. All subjects proceeded to lever press training after two sessions.
Errorless training. Errorless training sessions lasted 20 min per day and were
conducted 6 days per week. Animals were initially trained to lever press either the left or
right lever and reinforcement was delivered under a fixed-ratio (FR) schedule that was
gradually incremented from FR 1 to FR 20 over the course the training sessions. Once
subjects were reliably lever pressing on the FR 20 schedule, errorless training sessions
commenced with either the left lever or right lever extended. During this phase, subjects
received i.p. injections of either 0.08 mg/kg LSD or saline 15 min prior to the beginning
of each session. Half the animals in each training group were reinforced for responses on
the right lever following drug injections (D) and for responses on the left lever following
saline vehicle injections (V). Conditions were reversed for the remaining animals in each
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group. Once subjects were responding reliably on an FR 20 schedule on both the drug-paired and
vehicle-paired levers, discrimination training commenced.
Discrimination training. Both left and right levers were present during discrimination
training sessions. These sessions were 20 min in duration and were conducted only once per day,
6 days a week. Similar to the preliminary training sessions, responding was initially reinforced
under a FR 1 schedule that was progressively incremented to a FR 20 schedule under drug and
vehicle conditions. Once animals were reliably responding under the FR 20 schedule under both
drug and vehicle conditions, this schedule remained in effect for the remainder of the training
sessions. Drug and vehicle training sessions were alternated with sessions under the same
stimulus conditions occurring no more than twice consecutively. The performance criteria for
stimulus control was a minimum of eight out of ten consecutive discrimination trials with an 80
% or better correct lever response prior to delivery of the first reinforcer and for the total session.
Stimulus substitution testing. Stimulus substitution tests commenced when each subject
met the criteria for discrimination training. All subjects completed a minimum of one drug and
one vehicle training session between substitution test sessions and were required to meet the 80
% appropriate responding prior to the first FR and throughout the duration of each session on the
most recent drug and vehicle training sessions prior to each test session. All compounds were
administered via i.p. injection 15 min prior to commencing test sessions. Test sessions were
conducted under extinction and ended immediately following the completion of 20 consecutive
responses on either lever or until 20-min elapsed, which ever occurred first. Every subject was
tested on the same dose on test days. Substitution tests occurred no more than two times per
week with the test compounds presented in Table 1.
Table 1
Compounds for Substitution Tests
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Test Compound
Dose (mg/kg)
LSD
0.01, 0.02, 0.04, 0.08
DOM
0.125, 0.25, 0.5, 1
(±) MDMA
0.75, 1.5, 3
Mescaline
2.5, 5, 10
(+)-MDMA
0.75, 1.5, 3
(-)-MDMA
0.75, 1.5, 3, 4.5
MDPV
0.1, 0.3, 1, 3
4-MMC
0.3, 1, 3
(+)-MDA
0.75, 1.5, 3
(-)-MDA
0.75, 1.5, 3
Psilocybin
0.25, 0.5, 1.0
Cocaine
1.0, 3.0, 10
Amphetamine
0.1, 0.3, 1
*Drugs were tested in the order and dose depicted above
Antagonism testing. Antagonist testing began after all substitution drugs have
been tested. All subjects completed a minimum of one drug and one vehicle training
session between antagonist test sessions and were required to meet the 80 % appropriate
responding prior to the first FR and throughout the duration of each session on the most
recent drug and vehicle training sessions prior to each test session. All compounds were
administered via i.p. injection 60-min pre-session, except for pirenperone, which was 30min prior to commencing test sessions. Test sessions were conducted under extinction
and ended immediately following the completion of 20 consecutive responses on either
lever or until 20 minutes elapsed, which ever occurred first. Every subject was tested on
the same dose on test days. Antagonist tests occurred no more than two times per week
with the test compounds presented in Table 2.

Table 2
Compounds for Antagonist Tests
Test Compound
WAY-100,635

Dose (mg/kg)
0.4, 0.8, 1.6
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MDL-100,907
0.1, 0.05, 0.025
Haloperidol
0.5, 0.25, 0.125
SCH-23390
0.3, 0.1, 0.03, 0.01
Pirenpirone
0.64, 0.32, 1.28
*Drugs were tested in the order and dose depicted above
Data Analysis
Acquisition of drug stimulus control was determined by the number of discrimination
training sessions required to reach criteria in each sex. The mean (±SEM) number of sessions to
criterion was calculated for each training group and statistically analyzed with a t-test. Doseresponse curves were graphed for each training drug and test compound, with the mean (±SEM)
percentage of drug-appropriate lever responses as well as the mean (±SEM) response rate (lever
presses per second) plotted as a function of dose.
Dose response curves and response rates were statistically analyzed using General Linear
Model (GLM) with training drug as a between-subject comparison and test dose as a withinsubject comparison. For drugs that produced full substitution (80 % or higher drug-lever
responding at any dose), a nonlinear regression was conducted on the dose-response curve to
estimate effective dose 50 (ED50) values. Statistical analyses were conducted, and graphs were
created using GraphPad Prism (version 6.0) (La Jolla, CA, USA) and Minitab (version 17)
software (State College, PA, USA).
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CHAPTER III
RESULTS
Discrimination Acquisition
All subjects acquired the LSD – saline discrimination within 40 sessions.
The acquisition of 0.08 mg/kg LSD vs. saline discrimination is illustrated in Figure 1A.
The mean ± S.E.M. number of discrimination training sessions to meet testing criteria
was 25.50 sessions (SD = 10.9) for males and 25.75 (SD = 7.80) for females. Overall,
there was no statistically significant difference in discrimination acquisition or on number
of responses between males and females. However, there was a statistical significant
effect of sex on total response rate between males and females [F[1,14] = 13.15, p ≤ 0.01],
with males having higher total response rate (see figure 1B).

Discrimination Acquisition
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Figure 1. Learning curves of male and female rats trained to discriminate 0.08 mg/kg LSD from
saline vehicle. Filled circles (●) represent the data obtained from males and filled squares ()
represent data from females. Each data point represents the mean (± SE) for (A) percentage of
LSD-lever selection, solid lines represent 0.08 mg/kg LSD and dashed lines represent saline and
(B) Total number of response per second.
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LSD Dose-Response Curves
Figure 2A-B illustrates the dose-response curves following administration of various
doses of LSD (0.01- 0.08 mg/kg) for both males and females. LSD produced dose-dependent
increases in LSD-appropriate responding in both sexes (Figure 2A-B top panel). Figure 2A
illustrates the LSD dose-response curve prior to the administration of any other test compounds
(~12 weeks). LSD dose-dependently increased LSD-lever selection up to the 0.08 mg/kg
training dose, which was the only dose to fully-substitution in males and females. The ED50
value for LSD discrimination was slightly higher in the females compared to males (males ED50
= 0.015; 95% Confidence Interval [CI] = 0.01 - 0.03 mg/kg) and (females ED50 = 0.023; 95% CI
= 0.02 – 0.03 mg/kg), respectively. The slopes of the dose-response curves did not differ
significantly between males and females. Response rates after saline administration and LSD
administration also were very similar in males and females (Figure 1A bottom panel). There
were no statistical significant effect on response rate.
After the completion of all substitution tests (~ 41 weeks), the LSD dose-response curve
was generated again (Figure 2B). LSD dose-dependently increased LSD-lever selection up to
the 0.08 mg/kg training dose. LSD 0.04 mg/kg and 0.08 mg/kg fully-substituted in males and
females (males ED50 = 0.024 mg/kg; 95% CI = 0.00 – 1.55 mg/kg) and (females ED50 = 0.02;
95% CI = -1.82 – 1.61 mg/kg). The ED50 value was slightly higher in the males compared to the
females; however, the slopes of the dose-response curves did not differ significantly between
males and females. Visual inspection of the curve reveals that the females have higher LSDlever responding at all test doses. Response rate was not significantly different between sexes or
doses.
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LSD Dose-Response Curve
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Figure 2: LSD dose-response curves of male and female rats trained to discriminate 0.08 mg/kg
LSD from saline vehicle. Filled circles (●) represent the data obtained from males and filled
squares () represent data from females. Each data point represents the mean (± SE) for (A)
LSD dose-response curve approx. 12 weeks (B) LSD dose-response curve approx. 41 weeks.
LSD Time-Course Curve
Results of the time course tests with 0.08 mg/kg LSD in male and female SD rats
are illustrated in Figure 3. The results indicated the onset to the effect (≥ 20% drugappropriate responding), peak activity and complete substitution (≥ 80% drug-appropriate
responding) occurred by 15 and 30 min post-injection in both males (99%) and females
32

(99%). A time-dependent decline in LSD-lever responding was evident in both males and
females, with partial substitution observed at 60, 90, 120 min. There was no overall sex
difference in percentage LSD-appropriate responding during time course tests. However, visual
inspection of figure 3 (top panel) displays higher partial substitution in males compared to
females at 90 and 120 min post-injection. Statistical analysis failed to detect a significant main
effect of time or sex on response rate.
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Figure 3: Time course for the discriminative stimulus effects of LSD (0.08 mg/kg) administered
at 15, 30, 60, 90, and 120 min pre-injection. Percentage LSD-appropriate responding (top panel)
and response rate (bottom panel) in males (●) and females (). Data points represent group
means (± S.E.M.) at each time point.

Substitution Tests
The results obtained from General Linear Model (GLM) analyses of the percentage LSDlever selection and response rate for each test compound assessed for substitution is depicted in
Table 3.
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Table 3: Statistical Analysis of Substitution Tests
Test Drug
DOM

df
F (%D)
df
F (Rate)
a
[3,52] DOSE =
9.11
[3,56] DOSE =
3.96b
[1,52] SEX=
0.57
[1,56] SEX=
0.251
[3,52] DOSE*SEX= 0.32
[3,56] DOSE*SEX= 1.49
MESCALINE [2,42] DOSE =
22.82a
[2,42] DOSE =
7.80a
a
[1,42] SEX =
15.27
[1,42] SEX=
4.97b
[2,42] DOSE*SEX= 9.83a
[2,42] DOSE*SEX= 2.56
PSILOCYBIN [2,42] DOSE =
7.64a
[2,42] DOSE=
3.07
[1,42] SEX=
0.08
[1,42] SEX=
2.40
[2,42] DOSE*SEX= 0.82
[2,42] DOSE*SEX= 0.98
(±)MDMA
[2,36] DOSE=
2.75
[2,42] DOSE=
5.97b
[1,36] SEX=
1.60
[1,42] SEX=
8.37b
[2,36] DOSE*SEX= 0.74
[2,42] DOSE*SEX= 2.23
(+)-MDMA
[2,32] DOSE=
0.52
[2,42] DOSE=
1.77
[1,32] SEX=
3.85b
[1,42] SEX=
2.53
[2,32] DOSE*SEX= 0.34
[2,42] DOSE*SEX= 0.08
(-)-MDMA
[2,32] DOSE=
0.37c
[3,56] DOSE=
3.91b
b
[1,32] SEX=
4.45
[1,56] SEX=
3.22
[2,32] DOSE*SEX= 0.45
[3,56] DOSE*SEX= 0.10
(+)-MDA
[2,30] DOSE=
2.49c
[2,42] DOSE=
4.74b
[1,30] SEX=
0.07
[1,42] SEX=
0.01
[2,30] DOSE*SEX= 1.37
[2,42] DOSE*SEX= 0.02
(-)-MDA
[2,33] DOSE=
3.35a
[2,42] DOSE-=
3.22b
[1,33] SEX=
1.51
[1,42] SEX=
1.94
[2,33] DOSE*SEX= 0.39
[2,42] DOSE*SEX= 2.75
MDPV
[2,38] DOSE=
2.63
[3,56] DOSE=
3.14b
[1,38] SEX=
0.32
[1,56] SEX=
0.57
[2,38] DOSE*SEX= 0.45
[3,56] DOSE*SEX= 0.61
4-MMC
[2,39] DOSE=
0.61
[2,42] DOSE=
2.65
[1,39] SEX=
8.53b
[1,42] SEX=
2.64c
[2,39] DOSE*SEX= 0.72
[2,42] DOSE*SEX= 0.28
COCAINE
[2,36] DOSE=
0.24
[2,42] DOSE=
1.21
1,36] SEX=
7.84b
[1,42] SEX=
5.03b
[2,36] DOSE*SEX= 0.31
[2,42] DOSE*SEX= 1.42
AMPH
[1,26] DOSE=
1.42
[3,55] DOSE=
4.54b
(males n=7) [1,26] SEX=
0.67
[1,55] SEX=
2.10
[1,26] DOSE*SEX= 0.54
[3,55] DOSE*SEX=
0.31
Note. Each dose response curve was analyzed using GLM. DOSE=treatment; Sex=difference between
males (n=8) and females (n=8); DOSE*SEX= interaction
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a

p< 0.001; b p< 0.05.

Hallucinogens
Substitution test results with three classical hallucinogens are presented in Figure
4A-C. Percentage LSD-lever selection and response rates following substitution tests with DOM
(0.125 - 1 mg/kg) are illustrated in figure 4A. DOM completely substituted in the males at the
0.5 mg/kg (86%) and partially substituted at the 1 mg/kg (72%) (males ED50 = 0.26 mg/kg; CI =
0.13 – 0.5 mg/kg). DOM completely substituted in females at the 0.5 mg/kg (97%) and 1 mg/kg
(88%) (females ED50 = 0.22 mg/kg; CI = 0.13 – 0.37 mg/kg) and partially substituted at 0.125
mg/kg DOM. Statistical analysis revealed a significant main effect of test dose on percentage
LSD-lever responding, but no significant effect of sex. Tukey’s post hoc test were significant
between 0.125 mg/kg and both the 0.5 mg/kg (p < 0.001) and 1 mg/kg (p < 0.01), between 0.05
mg/kg and the 0.25 mg/kg (p < 0.0001), and between the 0.25 mg/kg and the 1 mg/kg (p <
0.001) test doses. Statistical analysis of response rate revealed a significant main effect of dose,
but not of sex. Tukey’s post hoc test was significant between 0.125 mg/kg and both the both the
0.5 mg/kg (p < 0.03) and 1 mg/kg (p < 0.001) test doses.
The percentage LSD-lever selection and response rates with mescaline (2.5 - 10 mg/kg)
are illustrated in Figure 4B. Mescaline dose-dependently increased LSD-lever selection up to the
10 mg/kg dose in the females. Mescaline fully substituted in the females after the 10 mg/kg (90
%) test dose (ED50 = 5.505 mg/kg; CI = 0.5998 – 0.8882 mg/kg) and partially substituted after
the 5 mg/kg (76%) test dose. In the males, 10 mg/kg mescaline partially substituted for LSD (60
%) and the 5 mg/kg test dose engendered vehicle-appropriate responding. Statistical analysis
revealed a significant main effect of dose, sex, and dose x sex interaction on percentage LSDlever selection. Tukey’s post hoc test was significant between males and females at the 5 mg/kg
and 10 mg/kg dose (p < 0.0001) with higher percentage-LSD lever selection in females. Tukey’s
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post hoc test were significant between the 2.5 mg/kg and both 5 mg/kg (p < 0.01) and 10
mg/kg (p < 0.0001) and between the 5 mg/kg and 10 mg/kg (p< 0.005) test doses.
Response rates following mescaline tests are illustrated in Figure 4B (bottom panel).
Statistical analysis revealed a statistically significant main effect of dose and sex (see
table 3). Tukey’s post hoc test revealed significant effect of sex with higher response rate
in males than females at both the 5 mg/kg (p ≤ 0.05) and 10 mg/kg (p ≤ 0.01) test doses.
Tukey’s post hoc test revealed a statistically significant difference between response rates
following 2.5 mg/kg and 10 mg/kg test dose (p < 0.05) and between 5 mg/kg and 10
mg/kg (p < 0.001).
The percentage LSD-lever selection and response rates with psilocybin (0.25 - 1
mg/kg) are illustrated in Figure 4C. Psilocybin dose-dependently increased LSD-lever
selection up to the 1 mg/kg dose in both sexes. The highest dose of psilocybin (1 mg/kg)
substituted completely in the females (84%) (ED50 = 0.41 mg/kg; CI= (-0.52 – 0.24) and
partially substituted in the males (78%). Statistical analysis revealed a significant main
effect of test dose on percentage of LSD-lever responding, but no significant main effect
of sex. Tukey post hoc test revealed a significant difference between the 0.25 mg/kg and
both the 0.5 mg/kg (p < 0.005) and 1 mg/kg (p < 0.001) test doses. There was no
statistically significant effect of dose or sex on response rate. However, visual inspection
of figure 4C (bottom panel) reveals the response rate was higher in the males than the
females at 0.25 mg/kg and 0.5 mg/kg test doses, respectively.
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Figure 4: Results of substitution tests with three hallucinogens (A) DOM, (B) mescaline,
and (C) psilocybin in males (●) and females () trained to discriminate 0.08 mg/kg LSD from
saline. Mean (± S.E.M.) percentage LSD-lever selection (top panel) and response rate (bottom
panel).

MDMA and MDMA Isomers
The results of substitution tests with (±)MDMA, (+)-MDMA, and (-)-MDMA are shown
in Figure 5A-C. The percentage LSD-lever selection (top panel) and response rates (bottom
panel) with (±)MDMA (0.75- 3 mg/kg) are illustrated in figure 5A. The highest dose of
(±)MDMA (3 mg/kg) substituted partially for LSD in only the males (69%). There was no
statistically significant main effect of dose or sex. Statistical analysis revealed a significant main
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effect of dose and of sex on MDMA response rate (see Table 5). Tukey’s post hoc test revealed
a significant effect on response rate at 0.75 mg/kg (p < 0.05) and 1.5 mg/kg (p < 0.005) test dose
in the males compared to females. Tukey’s post hoc test was significant (p between the 3 mg/kg
and both the 0.75 mg/kg (p < 0.005) and 1.5 mg/kg (p < 0.01) test doses.
Figure 5B illustrates the percentage LSD-lever selection (top panel) and response
rates (bottom panel) following (+)-MDMA (0.75 – 3 mg/kg). None of the (+)-MDMA
test doses substituted in males or females. Statistical analysis revealed a significant main
effect of sex on percentage LSD-lever responding. Tukey’s post hoc test revealed
significant effect of sex, males having higher LSD-lever responding at 3 mg/kg (p < 0.05)
test dose compared to females. Statistical analysis failed to reveal a significant effect on
response rate of dose or sex.
The percentage LSD-lever selection (top panel) and response rates (bottom panel)
with (-)-MDMA (0.75 – 3 mg/kg) are illustrated in Figure 5C. The highest dose of (-)MDMA (3 mg/kg) partially substituted for LSD in the females (65%). No test doses of ()-MDMA substituted for LSD in the males. Statistical analysis revealed a significant
effect of dose on percentage of LSD-lever responding, but no significant effect of sex.
Tukey’s post hoc test revealed a significant difference between the 3 mg/kg and both the
0.75 mg.kg (p < 0.001) and 1.5 mg/kg (p < 0.01) test doses. Statistical analysis revealed
a significant effect of dose on response rate, but not sex. Tukey’s post hoc test revealed a
significant difference between 0.75 mg/kg and the 3 mg/kg (p < 0.01) test dose.
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Figure 5: Results of substitution tests with (A) (±)MDMA (0.75- 3 mg/kg), (B) (+)-MDMA
(0.75- 3 mg/kg), and (C) (-)-MDMA (0.75- 4.5 mg/kg) in males (●) and females () trained to
discriminate 0.08 mg/kg LSD from saline. Mean (± S.E.M.) percentage LSD-lever selection (top
panel) and response rate (bottom panel).

MDA Isomers
The percentage LSD-lever selection (top panel) and response rates (bottom panel) with
(+)-MDA (0.75 - 3.0 mg/kg) are illustrated in Figure 6A. (+)-MDA 1.5 mg/kg (64%) and 3
mg/kg (62%) partially substituted in the males. None of the doses tested substituted for LSD in
the females. Statistical analysis revealed no significant effect of (+)-MDA dose or sex on
percentage of LSD-lever responding (see Table 5). Statistical analysis of response rate revealed
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a significant effect of (+)-MDA dose, but not of sex. Tukey’s post hoc test revealed a significant
difference between the 0.75 mg/kg and the 3 mg/kg (p < 0.004) test doses.
The percentage LSD-lever selection (top panel) and response rates (bottom panel)
following (-)-MDA (0.75 - 3.0 mg/kg) are illustrated in Figure 6B. (-)-MDA 1.5 mg/kg
(68%) and 3 mg/kg (73%) partially substituted in the females. None of (-)-MDA test
doses substituted in the males. Statistical analysis revealed no significant effect of (-)MDA dose or of sex. Statistical analysis of response rates revealed a significant effect of
(-)-MDA dose, but not sex. Tukey’s post hoc test revealed a significant difference
between the 0.75 mg/kg and the 3 mg/kg (p < 0.01) test doses.
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Figure 6: Results of substitution tests with (A) (+)-MDA (0.75- 3 mg/kg), and (B) (-)-MDA
(0.75- 3 mg/kg) in males (●) and females () trained to discriminate 0.08 mg/kg LSD from
saline. Mean (± S.E.M.) percentage LSD-lever selection (top panel) and response rate (bottom
panel).
40

Synthetic Cathinones
The percentage LSD-lever selection (top panel) and response rates (bottom panel) with
MDPV (0.1 – 3 mg/kg) are illustrated in Figure 7A. MDPV 3 mg/kg partially substituted in the
females (71%). No test doses of MDPV substituted in the males. Statistical analysis failed to
reveal a significant effect of MDPV dose or sex on percentage of LSD-lever responding (see
Table 5). Statistical analysis on response rate revealed a significant main effect of dose, but not
on sex. Tukey’s post hoc test revealed a significant effect between the 0.1 mg/kg and both the
0.3 mg/kg (p < 0.04) and 3 mg/kg (p < 0.01) test doses and between the 1 mg/kg and 3 mg/kg (p
< 0.03) test doses.
The percentage LSD-lever selection (top panel) and response rates (bottom panel)
following 4-MMC (0.3 – 3 mg/kg) are illustrated in Figure 7B. The highest dose of 4-MMC (3
mg/kg) partially substituted in the females (68%). No test doses of 4-MMC substituted in the
males. Statistical analysis revealed a significant effect of sex, but not of dose. Tukey’s post hoc
test revealed a significant difference between males and females at 3 mg/kg test dose (p < 0.005).
Statistical analysis on response rate failed to reveal a significant effect of dose or sex.
Stimulants
The percentage LSD-lever selection (top panel) and response rates (bottom panel) with
cocaine (1 – 10 mg/kg) substation tests are illustrated in Figure 8A. No dose of cocaine
substituted for LSD in males or females. However, visual comparison indicated that the females
exhibited a higher percentage LSD-lever selection at all test doses compare to males. Statistical
analysis revealed a significant effect of sex, but not dose (see Table 5). Statistical analysis on
response rate revealed a significant effect of sex, but not of dose. Tukey’s post hoc test revealed
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a significant difference between males and females following 1 mg/kg (p < 0.05) and 3 mg/kg
cocaine (p < 0.05).
The percentage LSD-lever selection (top panel) and response rates (bottom panel)
following d-amphetamine (AMPH) (0.1 – 1 mg/kg) are illustrated in Figure 8B. One of
the male rats died during testing AMPH and its data are not included in the analysis.
Statistical analysis revealed no significant effect of AMPH dose or sex on percentage
LSD-lever responding. Statistical analysis on response rate revealed no significant main
effect of dose or sex.
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Figure 7: Results of substitution tests with (A) MDPV, and (B) 4-MMC in males (●) and
females () trained to discriminate 0.08 mg/kg LSD from saline. Mean (± S.E.M.) percentage
LSD-lever selection (top panel) and response rate (bottom panel).
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Stimulants
A

B

80

100

P e r c e n t L S D -L e v e r R e sp o n se s

P e r c e n t L S D -L e v e r R e sp o n se s

100

M ALES
FEM ALES

60

40

20

0

80

M ALES
FEM ALES

60

40

20

0
SAL

L S D 0 .0 8

1

3

10

SAL

L S D 0 .0 8

C o c a in e d o s e ( m g /k g )
1 .5

0 .3

1

1 .5

M ALES

M ALES

FEM ALES

N u m b er o f R esp on ses P er S econ d

N u m b er o f R esp on ses P er S econ d

0 .1

A M P H d o s e ( m g /k g )

1 .0

0 .5

0 .0

FEM ALES

1 .0

0 .5

0 .0
SAL

L S D 0 .0 8

1

3

10

SAL

C o c a in e d o s e ( m g /k g )

L S D 0 .0 8

.1

.3

1

A M P H d o s e ( m g /k g )

Figure 8: Results of substitution tests with (A) cocaine, and (B) d-amphetamine in males (●) and
females () trained to discriminate 0.08 mg/kg LSD from saline. Mean (± S.E.M.) percentage
LSD-lever selection (top panel) and response rate (bottom panel).

Antagonists Tests
Serotonin Antagonists
To determine the role of various 5-HT receptors in mediating the discriminative stimulus
effects of LSD, rats were pretreated with three 5-HT antagonists prior to the administration of
LSD (0.08 mg/kg). One male rat died prior to starting the antagonist tests.
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Table 4: Statistical analysis using a GLM on each antagonist administered prior to the
administration of 0.08 mg/kg LSD.
Test Drug
WAY 100,635

df
[3,48]
[1,48]
[3,48]
MDL 100,907
[3,48]
[1,48]
[3,48]
HALOPERIDOL [2,29]
[1,29]
[2,29]
SCH 23390
[3,33]
[1,33]

F (%D)
DOSE =
1.41
SEX=
0.34
DOSE*SEX= 1.02
DOSE =
10.86a
SEX =
0.86
DOSE*SEX= 0.97
DOSE =
1.26
SEX=
0.00
DOSE*SEX= 1.09
DOSE=
9.52a
SEX=
0.15

PIRENPIRONE

DOSE=
2.99
SEX=
2.15
DOSE*SEX= 1.90

[2,33]
[1,33]
[2,33]

df
[3,48]
[1,48]
[3,48]
[3,48]
[1,48]
[3,48]
[2,36]
[1,36]
[2,36]
[3,48]
[1,48]
[3,48]
[2,36]
[1,36]
[2,36]

F (Rate)
DOSE =
SEX=
DOSE*SEX=
DOSE =
SEX=
DOSE*SEX=
DOSE=
SEX=
DOSE*SEX=
DOSE=
SEX=
DOSE*SEX=
DOSE=
SEX=
DOSE*SEX=

2.52
4.32b
2.08
8.32a
5.54b
0.74
0.16
6.32b
2.24
5.31b
10.16b
0.30
2.71
0.41
0.57

Note. Each dose response curve was analyzed using a two-way repeated measures ANOVA
DOSE=treatment; Sex=difference between males (n=7) and females (n=8); DOSE*SEX=
interaction a p< 0.001; b p< 0.05.

5-HT Antagonists
Figure 9A shows the percentage LSD-lever selection (top panel) and response
rates (bottom panel) with WAY 100,635 (0.4 – 0.16) administered in combination with
LSD 0.08 mg/kg. None of the test doses of WAY 100,635 completely blocked the LSD
stimulus cue in males or females. However, 0.4 mg/kg and 0.8 mg/kg WAY 100,635
partially blocked the LSD stimulus cue in only males. Statistical analysis revealed no
significant effect of dose or sex (see Table 4). Statistical analysis on response rate
revealed a significant effect of sex, but not dose. Tukey’s post hoc tests revealed a

44

significant effect of sex (p < 0.05), with females having a higher rate of response at all of WAY
100,635 tests doses.
The percentage LSD-lever selection (top panel) and response rates (bottom panel)
following MDL 100,907 (0.025 – 0.1 mg/kg) administered in combination with LSD 0.08 mg/kg
are displayed in Figure 9B. MDL 100,907 completely blocked LSD stimulus cue at all doses
tested in males. Partial antagonism of the LSD cue at 0.05 mg/kg occurred in the females.
Statistical analysis revealed a significant effect of MDL 100,907 dose on percentage of LSDlever responses, but not sex. Tukey’s post hoc test was significant between the vehicle control
and 0.25 mg/kg (p < 0.002), 0.05 mg/kg (0.001), and 0.1 mg/kg (p < 0.005) test doses. Statistical
analysis on response rate revealed a significant effect of dose and sex. Tukey’s post hoc tests
revealed a significant effect of MDL100, 907 dose between the control dose and both 0.025
mg/kg (p < 0.001) and 0.05 mg/kg (p < 0.0001) and between 0.1 mg/kg and both 0.025 mg/kg (p
< 0.001) and 0.05 mg/kg (p < 0.002). Tukey’s post hoc tests revealed a significant effect of sex
(p < 0.05), males having higher response rate at all of the test doses compared to females.
The percentage LSD-lever selection (top panel) and response rates (bottom panel) with
pirenperone (0.32 – 1.28 mg/kg) administered in combination with LSD 0.08 mg/kg are
displayed in Figure 9C. Pirenperone completely attenuated the LSD stimulus cue at all of the
doses tested in the males. The intermediate dose of pirenperone (0.64 mg/kg) partially blocked
the LSD stimulus cue and the lowest (0.32 mg/kg) and highest (1.28 mg/kg) completely
antagonized the LSD cue in females. Statistical analysis of percentage LSD-lever selection and
on response rate failed to reveal a statistically significant effect of pirenperone dose or sex.
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Serotonin Antagonists
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Figure 9: Results of serotonin antagonist’s tests with (A) WAY 100,635, (B) MDL 100,907, and
(C) pirenperone in males (●) and females () trained to discriminate 0.08 mg/kg LSD from
saline. Mean (± S.E.M.) percentage LSD-lever selection (top panel) and response rate (bottom
panel).

Dopamine Antagonists
Figure 10 A shows the percentage LSD-lever selection (top panel) and response rates
(bottom panel) following SCH 23390 (0.010 – 0.3 mg/kg) administered in combination with
LSD 0.08 mg/kg. SCH 23390 failed to block the LSD stimulus cue at all tested doses in both
males and females. Statistical analysis on percentage LSD-lever responding failed to reveal a
significant main effect of SCH 23390 dose or sex (see Table 4). Statistical analysis on response
rate revealed a significant effect of dose and sex. Tukey’s post hoc test revealed a significant
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effect between SCH 23390 0.01 mg/kg and 0.1 mg/kg (p < 0.02). Tukey’s post hoc test revealed
a significant effect of sex (p < 0.05), females having a higher response rate at all test doses
compared to males.
The percentage LSD-lever selection (top panel) and response rates (bottom panel) with
haloperidol (0.125 – 0.5 mg/kg) administered in combination with LSD 0.08 mg/kg are
illustrated in Figure 10B. Haloperidol failed to attenuate the LSD stimulus cue at all of the doses
tested in both males and females. Statistical analysis on percentage LSD-lever responding failed
to reveal a significant effect of haloperidol of dose or sex. Statistical analysis on response rate
revealed a significant main effect on sex, but not on haloperidol dose. Tukey’s post hoc test
reveal a significant effect on response rate at 0.125 mg/kg ((p < 0.05), males having higher
response rate compared to females.
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Figure 10: Results of dopamine antagonist’s test with (A) SCH 23390, and (B) in males (●) and
females () trained to discriminate 0.08 mg/kg LSD from saline. Mean (± S.E.M.) percentage
LSD-lever selection (top panel) and response rate (bottom panel).
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CHAPTER IV
DISCUSSION
The purpose of this study was to investigate the discriminative stimulus effects of
LSD in adult male and female Sprague- Dawley rats (SD). This is the first known
preclinical study to investigate possible sex differences in the pharmacological
mechanisms contributing to LSD’s discriminative stimulus effects. The current results
obtained are consistent with previous LSD discrimination studies conducted in only male
rats (Appel, West, Rolandi, Alici, Pechersky, 1999; & Marona-Lewicka, et al., 2007;
Marona-Lewicka, et al., 2009; Glennon & Young, 2011). In the present study, there were
several sex differences in LSD discriminative stimulus effects across numerous
parameters. For example, sex differences were found in substitution tests with other
drugs (see Table 5). However, the average number of sessions to establish the LSD
discrimination and the potency of LSD were nearly equivalent in males and females.
The average number of sessions to establish LSD discrimination is in general
agreement with previous research in only male rats. For example, previous research has
suggested that the mean number of sessions to training criteria using 0.08 mg/kg LSD
was approximately 25 to30 sessions (Appel et al., 1999; & Glennon & Young, 2011). In
the present study, males and females did not differ in the acquisition of the LSD – saline
discrimination. The number of sessions to meet criteria was approximately 25 sessions
for both males and females. Additionally, the ED50 for LSD substitution in the present
study is within the range reported previously for males trained to discriminate LSD (~
0.037 mg/kg) (Appel et al., 1999; Nichols, 2004).
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Table 5: Substitution tests in male and female rats trained to discriminate LSD (0.08 mg/kg)
from saline
Test Compound

Males (n=8)

Females (n=8)

DOM

CS- 0.5
PS- 1
NS- 0.125, 0.25

CS- 0.5, 1
PS- 0.125
NS- 0.25
CS- 10, 5

Mescaline
PS-10
NS- 2.5, 5

(-)MDMA
(+)-MDA
(-)-MDA

Yes

NS- 2.5
CS- 1
PS- 0.5
NS- 0.25

Psilocybin

(±)MDMA

Statistical
Significant

PS- 0.5, 1
NS- 0.25
PS- 0.75, 1.5, 3

Yes
NS- 0.75, 1.5, 3
PS- 3
NS- 0.75, 1.5
PS- 0.75, 1.5, 3

PS-3
NS- 0.75, 1.5
PS- 1.5, 3
NS- 0.75
PS- 1.5, 3
NS- 0.75

PS- 1.5, 3
NS- 0.75
PS- 3
NS- 0.1, 0.3, 1
PS- 1, 3
NS- 0.3

MDPV
NS- 0.1, 0.3, 1, 3
4-MMC
NS- 0.3, 1, 3

Yes

Yes

Note: CS=complete substitution (≥80%); PS= partial substitution (60-80%); NS= no substitution
(≤ 60%).

Doses are in mg/kg.

Previous research in only male rats trained to discriminate LSD from saline indicates a
time course of LSD discrimination similar to that in the present study (Marona-Lewicka, et al.,
2007; Marona-Lewicka, et al., 2009; Nichols, 2004). In the present study, there were no
statistically significant differences between males and females regarding the time course of
LSD’s discriminative stimulus effects. However, visual inspection of Figure 3A indicates that at
90 min, females showed less LSD-appropriate responding (23%) compared to males (47%).
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LSD’s main mechanism of action is thought to be governed by 5-HT2A/C and 5HT1A receptors. Previous research has suggested that 5-HT2A/C and 5-HT1A receptors are
strongly influenced by female hormones, estrogen and progesterone (Cosgrove, Mazure,
& Staley, 2007; & Cyr, Landry, & Di, 2000). Thus, female sex hormones may influence
the expression and/or sensitivity of 5-HT receptors. Based on previous research we
might expect female sex hormones to play an important role in the sensitivity of the
serotonergic system to LSD’s interoceptive effects. However, further research is needed
to investigate pharmacological differences between males and females.
The current results regarding stimulus substitution with other hallucinogens are
consistent with previous research conducted only in male rats. For example, DOM, mescaline,
and psilocybin have all been shown to fully substitute for LSD in male rats discriminating a
range of doses of LSD (0.01 – 0.08 mg/kg) from saline (Glennon & Young, 2011; Appel et al.,
1999; & Nichols, 2004). Previous research has suggested that DOM, mescaline, and psilocybin
exert hallucinogen-induced stimulus control through common mechanisms of action with 5-HT
receptor sites (Nichols, 2004). In the current study, the main sex difference was that females
exhibited higher levels of LSD substitution with DOM, mescaline, and psilocybin than the males
(see table 5).
Previous research with male rats discriminating LSD are in general agreement
with the current results concerning (±)MDMA, (+)-MDMA, (-)-MDMA, (+)-MDA, and
(-)-MDA (Baker, et al., 1995; Baker & Taylor, 1997; & Baker, Virden, Miller, &
Sullivan, 1997). Previous research findings indicate the enantiomers of MDA and
MDMA differ in the extent to which they produce substitution in rats trained to
discriminate d-amphetamine (AMPH) or classical hallucinogens, such as LSD. For
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example, (+)-MDMA and (+)-MDA substituted for AMPH and (-)-MDMA and (-)-MDA
substituted for the hallucinogens DOM and LSD (Callahan & Appel, 1988).
Additionally, previous research has suggested that (+)-MDMA and (+)-MDA isomers are more
potent dopamine (DA) releasers, are more similar to d-amphetamine (AMPH), and cause more
disruption on operant responding than the (-)-MDMA and (-)-MDA isomers (Baker, et al., 1995;
Baker & Taylor, 1997; & Baker, et al., 1997). In contrast, (-)-MDMA and (-)-MDA isomers
bind to 5-HT2A receptors with a higher affinity, are more similar to classical hallucinogens, and
substitute for LSD (Baker & Taylor, 1997).
A somewhat unexpected result in the current study was that (+)-MDMA, (-)-MDMA,
(+)-MDA, and (-)-MDA had opposite patterns of partial substitution for LSD between males and
females. For example, males exhibited higher percentage of LSD-lever responding after the
administration of (+)-MDMA and (+)-MDA than females. On the contrary, females exhibited
higher percentage of LSD-lever responding after the administration of (-)-MDMA and (-)-MDA.
Previous research has suggested that there is some common mechanism between LSD and
MDMA, although LSD acts directly on 5-HT2 receptors while MDMA acts predominantly as a
5-HT releaser.. One plausible explanation for the discrepancy between the sexes is female’s sex
hormones influencing the expression and activity of 5-HT receptors in regulating the effects of
MDMA (Lazenka, Suyama, Bauer, Banks, & Negus, 2017). Another possible explanation for
higher LSD-lever responding by males following administration of (+)-MDMA and (+)-MDA is
the involvement of dopamine release. Previous research has suggested that dopamine systems
are altered by female sex hormones (Becker & Hu, 2009; Lazenka et al., 2017). Thus, females
may be more sensitive to serotonergic drugs, such as (-)-MDA and (-)-MDMA and males may be
more sensitive to dopaminergic drugs. However, this might not be evident with
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phenylakylamines, such as (±) MDMA and MDA stereoisomers. Further examination of
receptor mechanisms may elucidate any sex differences in the mechanisms underlying LSD’s
discriminative stimulus effects.
The general failure of stimulants to substitute for LSD in the present study also
agrees with previous research conducted only in male rats. For example, cocaine and damphetamine (AMPH) did not substitute for LSD in either sex in this study, and previous
studies in only male animals trained to discriminate LSD from saline suggested that
stimulants, such as AMPH did not substitute for LSD (Glennon & Young, 2011; MaronaLewicka, et al., 2005; & Marona-Lewicka, et al., 2009). However, even though cocaine
or AMPH did not substitute for LSD in either sex, there were statistically significant sex
differences in the percentage of LSD-lever responding. As a group, the females exhibited
higher LSD-lever responding than males following all doses of cocaine.
The majority of preclinical research investigating sex differences has been
conducted with stimulants. For example, previous research has suggested that females
showed a greater locomotor activation and higher breaking points in self-administration
studies than males after AMPH and cocaine administration (Becker & Hu, 2008; Craft &
Stratmann, 1996). Additionally, evidence has suggested that female rats have higher
basal levels and higher psychostimulant-induced dopamine release than males (Walker,
Francis, Cabassa, & Kuhn, 2001). These studies concluded that sex differences in the
activation of dopaminergic systems have been attributed to circulating hormones, as well
as dopaminergic functionality (Becker & Hu, 2008; Walker, et al., 2001).
The general pattern of the current results for the antagonist tests in male and
female rats agrees with previous LSD discrimination studies conducted in only male rats
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(see table 6). To determine the role of various 5-HT antagonists in mediating the discriminative
stimulus effects of LSD, rats were pretreated with increasing doses of WAY 100,635, MDL
100,907, and pirenperone. Additionally, rats were also pretreated with increasing doses of two
dopamine (DA) antagonists, haloperidol and SCH 23390. Overall, the main sex difference was
the 5-HT antagonists produced greater antagonism of LSD’s discriminative stimulus effects and
DA antagonists were more disruptive on response rate in the males than the females.

Table 6: Antagonist tests in male and female rats trained to discriminate LSD (0.08 mg/kg)
from saline
Test Compound

Males (n=6)

Females (n=8)

WAY 100,635

PB- 0.04, 0.8
NB- 1.6

PB- 0.4
NB- 0.8, 1.6

MDL 100,907

CB- 0.025, 0.05, 0.1

CB- 0.025, 0.1
PB- 0.05

Pirenperone

CB- 0.32, 0.64, 1.28

CB- 0.32, 1.28
PB- 0.64

Haloperidol

PB- 0.5
NB- 0.125, 0.25

NB- 0.125, 0.25, 0.5

SCH 23390
NB- 0.01, 0.03, 0.1, 0.3
NB- 0.01, 0.03, 0.1, 0.3
Note: CB=complete blockade (≥80%); PB= partial blockade (40-70%); NB= no blockade (≤
40%). Doses are in mg/kg

Previous drug discrimination studies have investigated the possible role for the 5-HT1A
receptor in the stimulus effects of LSD. WAY 100,635is typically used as a selective 5-HT1A
receptor antagonist. However, evidence from previous research with this antagonist has yielded
inconsistent results regarding antagonism of LSD discriminative stimulus effects. For example,
WAY 100,635 blocked LSD-lever responding (Reissig, et al., 2005; & Mertel et al., 2007).
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Conversely, other researchers have reported that WAY 100,635 had no effect on LSDlever responding (Gresch, Barrett, Sanders-Bush, & Smith, 2006; & Marona-Lewicka et
al., 2009). These authors suggested the effects of WAY 100,635 are mediated by
activating dopamine (D4) receptors and not by blocking 5-HT1A receptors Despite
discrepancies, in the present study WAY 100,635 did not completely block LSDappropriate lever responding in either sex. These findings support previous research that
5-HT1A receptors are not critically involved in the discriminative stimulus effects of
LSD.
MDL 100,907 a selective 5-HT2A receptor antagonist has been shown to
completely antagonize the LSD cue in male rats (Gresch et al., 2007; Marona-Lewicka, et
al., 2007; and Nichols, 2004). The results of the present study are consistent with
previous findings. However, MDL-100,907 produced differential effects between males
and females. As evident in figure 10B, the percentage of LSD-lever responding at all
MDL 100,907 doses was higher in the females than in the males and MDL 100,907
completely blocked the LSD cue at all of the doses tested. On the contrary, in the
females the highest (0.1 mg/kg) and lowest (0.025 mg/kg) MDL 100,907 doses
completely blocked the LSD cue; however, the intermediate dose of MDL 100,907 (0.05
mg/kg) only partially blocked the LSD cue. Thus, the sex difference in MDL 100,907
antagonism effects may reflect a minor sex difference in 5-HT receptor pharmacology.
More research is needed to investigate the 5-HT antagonists and female receptor
pharmacodynamics.
Numerous studies have demonstrated that the 5-HT2 receptor antagonist
pirenperone is highly efficacious at completely blocking the LSD stimulus cue (Colpaert,
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Carlos, Niemegeers, & Janssen, 1982; Cunningham & Appel, 1987; and Nichols, 2004). Results
of the present study agree with previous research conducted only in male rats. However, the
intermediate pirenperone dose (0.64 mg/kg) failed to completely attenuate the LSD stimulus cue
in the females. These results may reflect fluctuations in female hormones that impact 5-HT
receptor pharmacology .
To summarize, the selective 5-HT2A antagonist, MDL 100,907 and 5-HT2 antagonist
pirenperone significantly reduced LSD-lever responding, whereas the selective 5-HT1A
antagonist, WAY 100,635 did not significantly alter LSD discriminative stimulus. Dopamine
antagonists also failed to block LSD discrimination, although there were apparent sex differences
in the rate suppressant effects of these substances. These findings confirm previous research
suggesting a major role for the 5-HT2A receptor in mediating LSD’s psychoactive effects.
Limitations of the current study merit some discussion. One methodological constraint in
the present study is inherent in the drug discrimination paradigm. Specifically, this study was
conducted over an extended period of time (~15 months) and phases of the females’ estrous
cycles were neither measured nor controlled. Thus, the specific phases of the estrous cycle for
each individual female rat occurred at variable points throughout the duration of this experiment.
This methodological constraint may have introduced a source of variability in the data that could
have obscured the results of several test drugs. However, Prendergast, Onishi, and Zucker
(2014) conducted a meta-analysis examining the variability within male and female mice in 293
publications. Results suggested that compared to males, females were equally or even less
variable in all reported physiological and behavioral measures investigated (Prendergast, et al.,
2014). Additionally, Becker, McClellan, & Reed (2017) recently reported no significant sex
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differences when the estrous cycle in female rats was incorporated as a variable in several
behavioral assessments, such as the forced swim test and cocaine self-administration.
On the contrary, Páleníček et al., (2010) investigated the estrous cycle on the
behavioral activity of LSD. Females were divided into two groups: EP (estrus and
proestrus phases) and MD (metestrus and diestrus phases). Results suggested that LSD
mainly inhibited locomotor effects in the MD females, however in ED females, LSD
increased locomotor activity during the latter half of the testing period. Furthermore, EP
females showed less sensitivity to the disruptive effects of LSD on prepulse inhibition,
suggesting EP females were more protected against some of the effects of LSD. The
authors concluded that since sex hormones are at their highest level during estrus and
proestrus phases, female rats may have an increased number of 5-HT2A receptors
(Páleníček et al., 2010). Therefore, based upon this study, it is at least plausible that the
interoceptive effects of LSD may vary, contingent upon the estrous cycle phase at the
time of administration of LSD and other test compounds.
Another limitation to this study is LSD evokes a compound stimulus (Halberstadt
& Geyer, 2011; Winter, 2009). Although the main component of the LSD cue is
mediated through 5-HT2A receptors, LSD also binds with high affinity to a variety of
other monoamine receptors that may be responsible for minor elements of the LSD
stimulus cue. The minor elements of the LSD stimulus cue have been attributed to 5HT1A and DA D2 and D4 receptors (Appel et al., 1982; Marona-Lewicka and Nichols;
1995; & Nichols, 2004). It is possible that the most salient feature of a compound
stimulus varies among individual subjects, such that 5-HT2A receptor- mediated effects of
LSD might be the most salient feature in some subjects but not others. Therefore, sex
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differences observed in regard to stimulus substitution in the current study may be related to the
compound stimulus properties of LSD. The 5-HT2A component of the LSD cue may vary
between sexes and among individuals. Future research is required to tease out the differences in
receptor pharmacology of LSD in males and females.
Despite the aforementioned limitations of the current study, two conclusions may be
made. Male and female adult SD rats differ in the relative contributions of serotonergic and
dopaminergic activities to the LSD discriminative stimulus cue, including higher levels of LSD
substitution with 5-HT agonists, such as DOM, mescaline, psilocybin, (-)-MDMA, and (-)-MDA
in the females than the males and more complete antagonism of LSD discrimination by 5-HT
antagonists in males than the females. These findings may suggest that the LSD cue is
differentially mediated by 5-HT receptors in males and females. Previous research has suggested
that sexual dimorphisms exist in the 5-HT system of the rat brain. For example, striatal 5-HT
levels are higher in female SD rats than males (Páleníček et al., 2010). Additionally, female sex
hormones, estrogen and progesterone increase the density, expression, and sensitivity of 5-HT
receptors (Cosgrove et al., 2007). Therefore, female sex hormones may play an important role in
sensitivity to the LSD stimulus cue. Moreover, common mechanisms between drugs, such as
LSD and MDMA and MDA isomers that involve both serotonergic and dopaminergic mediation
of the discriminative cue may be altered by female sex hormones. Additionally, higher levels of
partial substitution by the synthetic cathinones in females and stronger response disruption by
dopamine antagonists in males may indicate sex differences in the contribution of dopamine to
LSD’s discriminative stimulus effects.
Sex is an important biological variable in both clinical and preclinical research.
Preclinical animal models aid in understanding the underlying mechanisms involved with drug
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action and the results of these studies lay the groundwork for clinical research. Since,
May of 2014 the NIH has been implementing policies regarding the inclusion of female
subjects in preclinical work. One of the biggest reasons for this reform in preclinical
research is the multitude of published articles that have documented sex differences in
gene expression and neurobiology that can affect the pharmacokinetics and
pharmacodynamics of drugs. Additionally, the need for preclinical research investigating
interactions of female sex hormones on the discriminative stimulus effects of LSD and
other drugs.
The results of the current study may be informative for future investigations with
clinical populations regarding possible sex differences in the subjective and
pharmacodynamic effects of LSD. Clinical experimental research with LSD is currently
undergoing a major revival and since 2014, numerous clinical reports investigating the
effects of LSD have appeared in the scientific press (Carhart-Harris, Walley, Bolstridge,
Feilding, and Nutt, 2014a; Carhart-Harris, et al., 2014b; Carhart-Harris, et al., 2016a;
Carhart-Harris, et al., 2016b; Gasser, et al., 2014; Schmid et al., 2014; Dolder, Schmid,
Haschke, Rentsch, & Liechti, 2015; Kaelen, et al., 2015; & Liechti, Dolder, & Schmid,
2017). Evidence from these studies has suggested that LSD has promising therapeutic
effects in treating various psychiatric disorders, such as anxiety, depression, and
treatment of alcoholism (Gasser, et al., 2014; & Dolder, et al., 2015). For example,
Gasser et al. (2014) suggested that LSD-assisted psychotherapy significant reduced
anxiety in participants diagnosis with a life-threatening disease for up to 12 months. LSD
has also been investigated in the treating of alcohol and opiate addiction. For example,
Krebs and Johnansen (2012) conducted a meta-analysis study investigating LSD’s effects
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in the treatment of alcohol. Results suggested that participants that received LSD had
significant decreases in alcohol misuse compared to the control group. Further
examination of sex differences in humans is warranted.
Future research using animal models of drug discrimination that examine the factors
discussed above may aid in establishing a better understanding regarding any sex differences in
neural mechanisms responsible for LSD’s interoceptive stimulus effects. Although the recent
trend in drug abuse research has been focusing on both male and females, it is apparent that more
research is necessary to clearly define the factors that contribute to sex differences in the
interoceptive stimulus effects of LSD and other illicit drugs.
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